Schizoaffective Disorders Completed Phase 4 Trials for Aripiprazole (DB01238)

Also known as: Schizoaffective disorder / Schizophrenia schizoaffective / Schizoaffective psychosis / Schizo-affective type schizophrenia

IndicationStatusPhase
DBCOND0033299 (Schizoaffective Disorders)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00330863Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating EfficacyTreatment
NCT00177008Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social AnxietyTreatment
NCT00208169Abilify Therapy for Reducing Comorbid Substance AbuseTreatment
NCT00224822The Effects of Aripiprazole on Patients With Metabolic SyndromeTreatment
NCT00304655Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS)Treatment
NCT00312598Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
NCT00325689Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.Treatment
NCT00423878Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective DisorderTreatment
NCT00520650Health Evaluation of Abilify Long-term TherapyTreatment
NCT00545467Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic AgentsTreatment